Compare · CANF vs RCUS
CANF vs RCUS
Side-by-side comparison of Can-Fite Biopharma Ltd (CANF) and Arcus Biosciences Inc. (RCUS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CANF and RCUS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- RCUS is the larger of the two at $2.92B, about 440.6x CANF ($6.6M).
- Over the past year, CANF is down 85.7% and RCUS is up 138.5% - RCUS leads by 224.2 points.
- CANF has been more active in the news (6 items in the past 4 weeks vs 3 for RCUS).
- RCUS has more recent analyst coverage (16 ratings vs 2 for CANF).
- Company
- Can-Fite Biopharma Ltd
- Arcus Biosciences Inc.
- Price
- $3.18+1.27%
- $23.48+1.23%
- Market cap
- $6.6M
- $2.92B
- 1M return
- -10.67%
- -5.26%
- 1Y return
- -85.68%
- +138.55%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2018
- News (4w)
- 6
- 3
- Recent ratings
- 2
- 16
Can-Fite Biopharma Ltd
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah-Tikva, Israel.
Arcus Biosciences Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Latest CANF
- SEC Form 6-K filed by Can-Fite Biopharma Ltd
- SEC Form 6-K filed by Can-Fite Biopharma Ltd
- Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism
- SEC Form 6-K filed by Can-Fite Biopharma Ltd
- SEC Form 6-K filed by Can-Fite Biopharma Ltd
- Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
- Can-Fite BioPharma upgraded by D. Boral Capital with a new price target
- SEC Form 6-K filed by Can-Fite Biopharma Ltd
- Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
- SEC Form 6-K filed by Can-Fite Biopharma Ltd
Latest RCUS
- Chief Accounting Officer Azoy Alexander sold $66,024 worth of shares (2,562 units at $25.77) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 39,581 units (SEC Form 4)
- Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
- Truist resumed coverage on Arcus Biosciences with a new price target
- Chief Financial Officer Goeltz Ii Robert C. sold $198,966 worth of shares (7,763 units at $25.63) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 84,161 units (SEC Form 4)
- Director Ribas Antoni gifted 5,050 shares, decreasing direct ownership by 12% to 38,600 units (SEC Form 4)
- SEC Form 144 filed by Arcus Biosciences Inc.
- SEC Form 144 filed by Arcus Biosciences Inc.
- SEC Form 10-Q filed by Arcus Biosciences Inc.
- Arcus Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update